Medicare GLP-1 Coverage: What Part D Pays Now

Medicare's position on GLP-1 drugs used to be simple and unpopular: if the prescription was for weight loss, Part D would not pay for it. That is still the default. What changed on July 1, 2026 is that a federal demonstration now sits alongside the default and pays for a narrow group of people, and the two things are easy to confuse. Everything below comes from CMS and Medicare.gov pages read on 2026-08-29. Prices checked 2026-08-29.

The rule underneath everything

Part D's definition of a covered drug incorporates the Medicaid exclusion list: a Part D drug does not include the categories "which may be excluded from coverage or otherwise restricted under Medicaid under sections 1927(d)(2) or (d)(3) of the Act, except for smoking cessation agents"⁵. The first item on that statutory list is "Agents when used for anorexia, weight loss, or weight gain"⁶.

That single clause is the whole history. A GLP-1 prescribed to treat type 2 diabetes has always been a Part D drug. The same molecule prescribed to reduce weight has not been, which is why coverage has hinged on the reason written on the prescription rather than on the drug in the box.

What opened on July 1, 2026

CMS describes the new program in its own words: the Medicare GLP-1 Bridge is "a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027"². The agency's launch announcement puts the cost plainly, saying eligible people "can obtain certain GLP-1 medications to lose weight or maintain weight reduction at a predictable and affordable cost of $50 per month"³.

Structurally it is not Part D coverage at all. CMS states that the program "will operate outside of the Medicare Part D benefit's coverage and payment flow," that plan sponsors do not have to opt in for their members to use it, and that in 2026 a single central processor handles prior authorization, claims and payment to pharmacies². It runs on demonstration authority, not on a change to the exclusion above.

Which drugs, and which forms

The Medicare fact sheet names three products and one exclusion inside a product line: Foundayo tablets, Wegovy as injection or tablet, and the Zepbound KwikPen only — the single-dose Zepbound pen and Zepbound vials are not covered¹. Medicare.gov repeats the same list on its coverage page⁴.

That form-level detail is the part most likely to catch someone out. A reader who has been on Zepbound single-dose pens does not simply keep filling them at $50. What Lilly charges cash for each Zepbound and Foundayo strength is in GLP-1 cost without insurance, and the pill's own ladder is in Foundayo cost.

Who qualifies

The fact sheet sets four requirements, all of which must be met¹.

You need Part D drug coverage, through a standalone drug plan or a Medicare health plan that includes drug coverage. Private fee-for-service plans, cost contract plans and PACE organizations are named as not qualifying.

You must not already be eligible to get a GLP-1 through your own Medicare drug plan. If your plan has been paying for one for any reason, you stay with your plan. The fact sheet defines GLP-1 drugs for this purpose as products containing semaglutide, tirzepatide, orforglipron, dulaglutide or liraglutide.

You must not have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease. Those are covered indications, and Medicare.gov's own eligibility tool says so in as many words: a person with them is not eligible for the Bridge "because your Medicare drug plan should cover GLP-1 medications to treat these conditions"⁴.

And you must be at least 18 with one of three clinical profiles: a BMI of 35 or higher; a BMI of 30 or higher with certain types of heart failure, hard-to-control high blood pressure, or chronic kidney disease at stage 3a or above; or a BMI of 27 or higher with prediabetes, or a previous heart attack, stroke, or blocked arteries in the legs or arms¹.

Your prescriber submits a prior-authorization form, and must certify that the drug is being used as part of a lifestyle program built around diet and exercise⁴. Approval is good for refills and dose changes through December 31, 2027 unless you switch GLP-1s⁴.

What the $50 does not do

The copay is flat regardless of income, and it is deliberately walled off from the rest of your drug benefit. CMS states that the Part D deductible does not apply, that no part of the $50 counts toward your true out-of-pocket total, and that there is no low-income subsidy for beneficiaries who would otherwise receive one². The fact sheet adds that these drugs are not eligible for the Medicare Prescription Payment Plan¹.

For a beneficiary with high total drug spending, that matters. Twelve months of Bridge fills move you no closer to the catastrophic threshold on everything else you take.

The route most people should check first

If a GLP-1 is clinically indicated for something other than weight itself, your existing plan is the better question. Semaglutide's cardiovascular indication rests on SELECT, which reported a lower rate of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease but without diabetes⁷; the background is in GLP-1, the heart and the kidneys. Tirzepatide's sleep-apnea indication rests on SURMOUNT-OSA⁸, covered in Zepbound and sleep apnea. Both are Part D territory today, and neither goes through the Bridge.

What this does not fix, and where telehealth sits

The Bridge is temporary, it excludes compounded products entirely, and it excludes anyone whose plan already covers a GLP-1. It also does nothing for people without Part D.

Telehealth is largely a separate economy from all of this. Of the 508 providers tracked here, only 6 mention Medicare in their published copy at all, and they point in both directions: one listing names Medicare and Medicaid among the plans it accepts, in the Klinic review, while another states it takes no Medicare, Medicaid or insurance of any kind, in the Contour Health review. 108 rows mention insurance in some form, which usually means help with a claim rather than a billed plan. If the Bridge does not reach you, the practical comparison is a cash one, ranked on best GLP-1 for weight loss and broken down in compounded semaglutide cost. Every source cited here is indexed in our research library.